Dr. Das’ research interests lie in the gastrointestinal (GI) cancer and phase I space. They revolve around designing early phase studies taking advantage of salvage DNA repair pathway dependence in biomarker selected GI tumors and overcoming the immunosuppressive tumor microenvironment in refractory tumors through mechanism-based immunotherapy combinations. Clinically, he takes care of patients with advanced GI malignancies with a specific interest in those with neuroendocrine tumors and colorectal, pancreatic, and gastric adenocarcinoma.
Dr. Das is currently pursuing a Master in Science and Clinical Investigation (MSCI) through Vanderbilt University Medical Center and the K12 VCORCDP grant. He completed an early phase externship at CTEP (investigational drugs branch) and participated in the FDA ASCO Fellow’s Day program. He has been fortunate to present at several national meetings including ASCO, GI ASCO, and ECOG.